UnitedHealth Group (UNH) director reports 279 deferred stock units grant

Rhea-AI Filing Summary

UnitedHealth Group Inc. director Charles D. Baker reported a routine equity compensation transaction. On 01/02/2026, he acquired 279 deferred stock units of UnitedHealth Group common stock at a price of $0 per unit. These deferred stock units are granted as regular quarterly compensation for service as a director and are immediately vested, but must be retained until he completes his service on the Board. Following this grant, he beneficially owns 1,806 shares/deferred stock units on a direct basis.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Baker Charles D.

(Last) (First) (Middle)

C/O UNITEDHEALTH GROUP INCORPORATED

1 HEALTH DRIVE

(Street)

EDEN PRAIRIE MN 55344

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITEDHEALTH GROUP INC [ UNH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		279(1)	A	$0	1,806	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents deferred stock units that are granted as regular quarterly compensation for service as a director of UnitedHealth Group. Deferred stock units are immediately vested, but must be retained by the director until the director's completion of service on the Board.

Remarks:

	Faraz A. Choudhry, Attorney-in-Fact for Charles D. Baker	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UNH director Charles D. Baker report?

Charles D. Baker, a director of UnitedHealth Group Inc., reported acquiring 279 deferred stock units of UnitedHealth Group common stock on 01/02/2026 as director compensation.

How many UnitedHealth Group (UNH) shares or units does Charles D. Baker own after this transaction?

After the reported transaction, Charles D. Baker beneficially owns 1,806 shares/deferred stock units of UnitedHealth Group common stock, held with direct ownership.

What are the deferred stock units granted to the UnitedHealth Group (UNH) director?

The filing states the 279 units are deferred stock units granted as regular quarterly compensation for service as a director of UnitedHealth Group. They are immediately vested but must be retained until the director completes Board service.

Was cash paid for the UnitedHealth Group (UNH) deferred stock units acquired by the director?

No cash was paid for this grant. The table shows the 279 deferred stock units were acquired at a price of $0 per unit, reflecting non-cash director compensation.

Is the reported UnitedHealth Group (UNH) transaction a routine compensation event?

Yes. The explanation notes the deferred stock units are granted as regular quarterly compensation for service as a director of UnitedHealth Group, indicating a recurring compensation arrangement.

How long must the UnitedHealth Group (UNH) director hold the deferred stock units?

The filing explains that the deferred stock units are immediately vested but must be retained by the director until the director's completion of service on the Board.